Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer

Table 1 Baseline patient characteristics in second line therapy

Clinical features	80 patients
Sex
Male	38
Female	42
Median age (yr)	61.0
Histological diagnosis	67 (83.8)
OMS
0	31 (38.7%)
1	40 (50.0%)
2	7 (8.8%)
3	2 (2.5%)
Presence of primary tumor	55 (68.8%)
Gemcitabine
Median number of cycle	3.0 (1.0-12.0)
Median duration (mo)	3.3 (0.5-18.9)
Duration ≥ 4 mo	29 (36.2%)
Metastatic disease	77 (96.3%)
Hepatic	70.1%
Peritoneal	29.9%
Nodal	23.4%
Pulmonary	16.9%
Carbohydrate antigen 19-9
Initial median concentration (IU/mL)	741 (2.0-> 2000)
Elevated (> 60 IU/mL)	57 (89.1%)

Data are expressed as median values (range).